Drug updated on 9/14/2023
|Injection (intravenous; : 300 mg/15 mL (20 mg/mL))
|Integrin receptor antagonist
| Ongoing and
- For the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML.
- For inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.
Product Monograph / Prescribing Information
|Tysabri (natalizumab) Prescribing Information.
|Biogen Inc., Cambridge, MA
Systematic Reviews / Meta-Analyses
|Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
|Journal of Comparative Effectiveness Research
|Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Clinical Practice Guidelines
|AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease.
|American Gastroenterological Association: Gastroenterology
|Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis; report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology.
|American Academy of Neurology
|ACG clinical guideline: management of Crohn's disease in adults.
|The American Journal of Gastroenterology